TEE
AVEO

Tibra Equities Europe’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Tibra Equities Europe’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-49,200
Closed -$324K – 266
2021
Q2 		$324K Buy
+49,200
New +$339K 0.1% 134
2018
Q2 		– Sell
-25,856
Closed -$750K – 256
2018
Q1 		$750K Buy
+25,856
New +$756K 0.13% 95

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tibra Equities Europe's AVEO Position: Q3 2021 in Review

Tibra Equities Europe sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2021, closing a stake of 49,200 shares — an estimated $324K sold.

Tibra Equities Europe first reported a position in AVEO in Q1 2018 and held it in 2 quarters. The position peaked at $750K in Q1 2018. 52 funds tracked by Wall St. Rank hold AVEO as of Q3 2021.

  • Tibra Equities Europe reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 49,200 AVEO Pharmaceuticals, Inc. shares in Q3 2021, an estimated $324K.
  • Tibra Equities Europe first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Tibra Equities Europe's AVEO Pharmaceuticals, Inc. position peaked at $750K in Q1 2018.
  • 52 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.